US EditionHHS chief RFK Jr. says he’s ordered a ‘complete review’ of chemical abortion pill
- The Secretary of Health and Human Services, Robert F. Kennedy Jr., has initiated a comprehensive review of the abortion medication mifepristone in response to emerging safety concerns reported in 2025.
- The review was prompted by a controversial anti-abortion analysis from the Ethics and Public Policy Center, which reported higher rates of adverse events than FDA clinical trials indicated.
- Mifepristone, approved in 2000 and used in nearly two-thirds of U.S. Abortions in 2023, blocks progesterone to end early pregnancy, and its safety has been supported by hundreds of studies despite recent challenges.
- During Senate hearings, Kennedy emphasized that at minimum, changes to the drug’s labeling are necessary and requested that FDA Director Marty Makary take charge of an investigation that would provide recommendations based on new data.
- The review and political pressure could lead to stricter FDA regulations on mifepristone, potentially restricting access amid ongoing legal battles and legislative efforts, raising concerns about implications for reproductive care.
54 Articles
54 Articles
The Independent
The Independent (US)How ‘bogus’ science is pushing Trump officials to go after abortion drugs
Analysis: Health officials are reviewing a dubious report that claims dangerous complications from mifepristone. Public health researchers and scientists tell Julia Musto and Alex Woodward they’re extremely skeptical
MedPage Today
Anti-Aging, Acupuncture and Health NewsWaiting Period Extends Abortion Wait Beyond Mandatory 24 Hours
(MedPage Today) -- MINNEAPOLIS -- Mandatory 24-hour waiting periods between consent and abortion visits often resulted in much longer waits than required, a prospective survey study found. The median interval between the two visits was 3 days...
Abortion providers challenge FDA’s remaining mifepristone restrictions in federal court • South Dakota Searchlight
“We just want to ensure that the most popular method for abortion in Virginia and beyond is protected no matter who sits at the White House and who sits in the FDA,” said Whole Woman’s Health founder and president Amy Hagstrom Miller outside of the U.S. District Court of the Western District of Virginia in Charlottesville, Virginia, on May 19, 2025. (Photo by Charlotte Rene Woods/Virginia Mercury)CHARLOTTESVILLE, Va. — Abortion pills — and quest…
InsideNoVA.com
Abortion providers challenge FDA’s remaining mifepristone restrictions in federal court
CHARLOTTESVILLE, Va. — Abortion pills — and questions over their inherent safety — were back in federal court Monday. Unlike a lawsuit rejected by the U.S. Supreme Court last year, plaintiffs this time are not anti-abortion activists arguing medication abortion…
Coverage Details
Bias Distribution
- 67% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
